Qurient Entered into a Clinical Collaboration Agreement with MSD to Evaluate Q901 + Keytruda (pembrolizumab) for Advanced Solid Tumors
Shots:
- The companies collaborated to initiate the P-I/II study to evaluate the safety & efficacy of Q901 + Keytruda in patients with selected advanced solid tumors
- In animal studies, Q901 inhibits the growth of tumors in multiple murine cells and patient-derived xenograft models, incl. prostate cancer & other indication
- Q901 is a highly selective cyclin-dependent kinase 7 (CDK7) inhibitor that inhibits CDK7 in the human kinome. Qurient licensed the CDK7 inhibitor program from LDC and the Max-Planck Society at the discovery research stage. Qurient further optimized the program, finished the IND-enabling studies, and received the US FDA clearance for an IND application
Ref: PRNewswire| Image: MSD
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
